Access cutting-edge who grade 3 glioma treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Rochester location
Preparing your pre-screening questions…
Access who grade 3 glioma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related who grade 3 glioma treatment provided free
Check if you qualify for this who grade 3 glioma clinical trial in Rochester, MN
No-Cost Study Care
Local to Rochester
Convenient for MN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful in differentiating between disease that has come back after a period of improvement (recurrence) or that is growing, spreading, or getting worse (progression) and treatment effect in patients with glioma. Patients with glioma undergo frequent imaging for assessment of disease status. After first-line treatment however, the correlation between imaging findings and tumor activity can be confused, and surgery is often required for definitive diagnosis. The PET/CT scanner is an imaging machine that combines 2 types of imaging in a single scan. The PET scanner detects and takes pictures of where the radioactive imaging agent (68Ga PSMA-11) has gone in the body and the CT scanner uses x-rays to take structural pictures inside the body. PSMA PET also binds to neoplastic blood vessels, including those in gliomas. This study may help researchers learn whether GA-68 PSMA-11 PET/CT is useful for improving detection of tumor recurrence or progression, as opposed to treatment effects, in patients with gliomas.
Sponsor: Mayo Clinic
Yes, this clinical trial (NCT06444412) has an active research site in Rochester, MN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for who grade 3 glioma treatment options in Rochester, MN, this clinical trial (NCT06444412) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced who grade 3 glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all who grade 3 glioma clinical trials near you to find additional studies recruiting in your area.
See all brain cancer clinical trials recruiting in Rochester — not just this study.
Browse Brain Cancer Trials in Rochester →